Seagen Entered into an Exclusive License Agreement with LAVA Therapeutics for LAVA-1223 to Treat EGFR-Expressing Solid Tumors
- LAVA to receive $50M up front & is also eligible to receive ~$650M in development, regulatory & commercial milestones along with royalties. Under the terms of the agreement, Seagen will develop & commercialize LAVA-1223, a bispecific T cell engager that was designed to target & activate Vγ9Vδ2 (gamma delta) t cells in the presence of EGFR-expressing solid tumors
- Seagen to get an exclusive license globally for LAVA-1223 & also has an option to nominate ~2 additional tumor targets for bispecifics by using LAVA’s Gammabody platform
- The agreement enables Seagen to use its expertise along with global development & commercialization capabilities to develop targeted cancer therapies to improve the lives of patients
Ref: Seagen | Image: Seagen
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.